Skip to content

Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus.

Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus: A Randomized Controlled Trial.

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07141446
Enrollment
60
Registered
2025-08-26
Start date
2023-02-05
Completion date
2024-02-28
Last updated
2025-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus

Keywords

Oral Lichen Planus, Neem, Triamcinolone acetonide, corticosteroid, clinical trial

Brief summary

The goal of this clinical trial is to learn if Neem works to treat Oral Lichen Planus in adults. It will also learn about the safety of Neem in oral lesions. The main questions it aims to answer are: To compare the efficacy of 1.5% Neem Gel (Azadirachta Indica) versus 0.1% Triamcinolone Acetonide in treatment of Oral Lichen Planus (OLP) as a topical treatment modality for patients with OLP, Researchers will compare Neem to a corticosteroid (a standard treatment for Oral Lichen Planus) to see if Neem works to treat Oral Lichen Planus. Participants: In experimental group were given Neem Gel in Orabase formulations and control group with topical Triamcinolone acetonide oral paste to be used twice every day for 3 months Visit the clinic once every month for checkups.

Interventions

DRUGNeem gel

1.5% Neem Gel in orabase formulation, twice daily application for 3 months

DRUGTriamcinolone Acetonide

0.1% oral paste to be applied twice daily for 3 months

Sponsors

Goa Dental College
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patient with clinical & histopathological diagnosis of OLP. * Patient above 20 years of age. * Patient willing to participate in the study with informed consent. * Patient with recalcitrant OLP.

Exclusion criteria

* Patient with known allergic reaction to Triamcinolone Acetonide or Neem. * Patients with lichenoid lesions. * Patients with associated cutaneous lesions. * Pregnant or lactating females.

Design outcomes

Primary

MeasureTime frameDescription
Thongprasom's ScoreFrom enrollment to the end of the 3 monthsclinical severity of lesion
OLP Disease Severity ScoreFrom enrollment to the end of 3 monthsSite, size and severity of lesion
Visual Analogue ScaleFrom enrollment to the end of 3 monthsBurning sensation will be evaluated with Visual Analogue scale

Secondary

MeasureTime frameDescription
Hospital Anxiety and Depression ScaleFrom Enrollment to the end of 3 monthsAnxiety and depression evaluation among patients

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026